Figure 1 | Scientific Reports

Figure 1

From: PRMT5 inhibition shows in vitro efficacy against H3K27M-altered diffuse midline glioma, but does not extend survival in vivo

Figure 1

An epigenetic probe screen identified the PRMT family as necessary for DMG viability. (A) An overview of the method for viability screening of the epigenetic probe set. HSJD-DIPG-007 cells were seeded into one of two screens (either to grow adherently or as spheroids). The following day each inhibitor was added to a final concentration of 1 µM, alongside a DMSO vehicle control. After 7 days of treatment, the relative viability was measured with the CellTiter-Glo assay. (B,C) Relative viability of HSJD-DIPG-007 adherent cell cultures after 7 days of growth in the presence of 1 µM of the indicated epigenetic inhibitor. Data points are the mean of 3 (B) or 4 (C) technical repeats annotated with the SD. Data points for probes that significantly reduced HSJD-DIPG-007 viability are depicted as green circles (multiple two-tailed t-tests, FDR = 1%). The names of PRMT family probes are highlighted in red and marked with a triangle.

Back to article page